Comparative Pharmacology
Head-to-head clinical analysis: AXERT versus ZOMIG ZMT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AXERT versus ZOMIG ZMT.
AXERT vs ZOMIG-ZMT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin 5-HT1B/1D receptor agonist; causes vasoconstriction of intracranial blood vessels and inhibits trigeminal nerve activation and release of vasoactive neuropeptides.
Selective serotonin 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial blood vessels, inhibits trigeminal nerve transmission, and reduces neurogenic inflammation.
AXERT (almotriptan malate) is administered orally. The recommended adult dose is 6.25 mg or 12.5 mg as a single tablet. If headache recurs, the dose may be repeated after 2 hours, with a maximum of 2 doses per 24-hour period (not exceeding 25 mg per day).
2.5 mg orally at onset of migraine; may repeat after 2 hours if needed. Maximum 10 mg in 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 26 hours (range 20-30 hours), supporting once-daily dosing for sustained antimigraine effect.
Terminal elimination half-life is approximately 3 to 3.5 hours for zolmitriptan and its active metabolite N-desmethyl zolmitriptan has a similar half-life. This supports a typical dosing interval of at least 2 hours between doses.
Approximately 57% of a dose is excreted in urine (10-15% unchanged, remainder as metabolites) and 38% in feces (primarily as metabolites) via biliary elimination.
Approximately 60-70% of the administered dose is excreted in urine, primarily as metabolites (active N-desmethyl zolmitriptan and inactive indoleacetic acid derivatives), with about 10-15% as unchanged drug. Fecal excretion accounts for about 20-30% of the dose.
Category C
Category C
Triptan Antimigraine
Triptan Antimigraine